A trial of extended-release niacin on top of statin therapy in patients with a history of CVD, high triglycerides, and low levels of HDL cholesterol has been halted prematurely, 18 months ahead of schedule, because niacin offered no additional benefits in this patient population. There was also a small, unexplained increase in ischemic stroke in the niacin group, but patients are being urged not to discontinue niacin without consulting their doctor.
Niacin Trial Halted Due to Stroke Concerns
Published on : Mon, 30 May 2011
Print as PDF